Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076751 · ClinicalTrials.gov registry record
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 82
- Enrollment target
NCT01076751 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 82 participants.
The verdict
NCT01076751 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 82 participants
- Enrollment target
Study Summary
Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others * Describe economic and patient-reported outcomes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01076751
The ClinicalTrials.gov registry entry for NCT01076751 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01076751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01076751 about?
NCT01076751 is a clinical study titled "Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients". Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to o...
What is the current status of trial NCT01076751?
This trial is currently terminated. The enrollment target is 82 participants. The study started on 2010-02. Estimated completion is 2010-10.
Who is sponsoring clinical trial NCT01076751?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.